20,438 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Caisse Des Depots ET Consignations

Caisse Des Depots ET Consignations purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,438 shares of the medical equipment provider’s stock, valued at approximately $1,473,000.

Other institutional investors have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares in the last quarter. FMR LLC raised its position in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after buying an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Hologic by 3.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock valued at $322,272,000 after buying an additional 129,035 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.4 %

HOLX opened at $62.32 on Friday. The firm’s fifty day simple moving average is $65.41 and its 200 day simple moving average is $73.50. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The stock has a market capitalization of $13.98 billion, a P/E ratio of 19.66, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HOLX. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Jefferies Financial Group began coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.